Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
Part of paid clinical trials in Mobile, Alabama.
- Sponsor
- Biotest
- Study ID
- NCT05722938
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Community-acquired Pneumonia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Trimodulin — DRUGIMP will be administered via IV infusion on 5 consecutive days
- Placebo (human albumin 1%) — DRUGIMP will be administered via IV infusion on 5 consecutive days
Study Details
The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with sCAP on invasive mechanical ventilation (IMV). Other objectives are to determine detailed pharmacokinetic (PK) properties of trimodulin in a PK substudy and to determine its pharmacodynamic (PD) properties.
Key Dates
- Start date
- Sep 9, 2023
- Status verified
- Feb 2026
- Primary completion
- Jul 31, 2028
- Completion
- Jul 31, 2028
Study Design
- Enrollment
- 590 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: TrimodulinTrimodulin (human IgM, IgA, IgG solution) for intravenous (IV) administration.
- Placebo Comparator: PlaceboHuman albumin 1%
Primary Outcome Measure
28-day all-cause mortality rate [ Time Frame: Between days 1-29 ]
Central Contacts
- Patrick Langohr+491732947122
- Claudia Schulte+4915222801491
Locations (19)
Find similar trials in Mobile, AL
Related Studies
- AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired PneumoniaPHASE3 · Recruiting · University of Manitoba · Chicago, Illinois
- Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactamsPHASE4 · Recruiting · Mayo Clinic · Scottsdale, Arizona